Evidence map›Paper›PMID 36047514›Full record

ArticleTurkish journal of pharmaceutical sciences2022

Evaluation of the Effect of Ethyl Acrylate-Methyl Methacrylate Copolymer in Racecadotril Dispersible Tablet.

Onur Pınarbaşlı, Burcu Bulut, Gülistan Pelin Gurbetoğlu, Nurdan Atılgan, Nagehan Sarraçoğlu, Asuman Aybey

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Onur PınarbaşlıILKO Pharmaceuticals, Research and Development Center, Ankara, Türkiye.ORCID 0000-0001-7091-683X
Burcu BulutILKO Pharmaceuticals, Research and Development Center, Ankara, Türkiye.ORCID 0000-0002-9726-8577
Gülistan Pelin GurbetoğluILKO Pharmaceuticals, Research and Development Center, Ankara, Türkiye.ORCID 0000-0003-1581-8473
Nurdan AtılganILKO Pharmaceuticals, Research and Development Center, Ankara, Türkiye.ORCID 0000-0003-2429-5483
Nagehan SarraçoğluILKO Pharmaceuticals, Research and Development Center, Ankara, Türkiye.ORCID 0000-0002-1222-7339
Asuman AybeyILKO Pharmaceuticals, Research and Development Center, Ankara, Türkiye.ORCID 0000-0001-7229-6435
Türk Telekom (Turkey) · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Racecadotril is an anti-diarrheal drug that has the indication to reduce the secretion of water and electrolytes into the intestine. It has an unpleasant taste, when administered orally. The presenting study developed a pharmaceutical racecadotril dispersible tablet, which masked the unpleasent taste using wet granulation method. For this reason, the effect of the number of ethylacrylate-methylmethacrylate copolymers (Eudragit Materials and Methods: Taste-masked racecadotril granules were prepared using Eudragit Results: Results of the studies have shown that the formulation should have Eudragit Conclusion: Our results demonstrated that a chemically long-term stable racecadotril dispersible tablet product, whose taste is efficiently masked using wet granulation method with an acceptable release profile was obtained with Eudragit

Indexed as

dispersible tabletethyl acrylate-methyl methacrylate copolymersRacecadotriltaste-maskingwet granulation

Identifiers

PMID36047514
PMCPMC9438762
OpenAlexW3207519832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.